Cargando…
Targeting RAD51 enhances chemosensitivity of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand break repair
RAD51, is a key homologous recombination protein that repairs DNA damage and maintains gene diversity and stability. Previous studies have demonstrated that the over-expression of RAD51 is associated with chemotherapy resistance of tumor cells to chemotherapy, and enhanced activity of DNA damage rep...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859462/ https://www.ncbi.nlm.nih.gov/pubmed/31638261 http://dx.doi.org/10.3892/or.2019.7384 |
_version_ | 1783471121365991424 |
---|---|
author | Yang, Meng Tian, Xiaoxue Fan, Zhuoyi Yu, Wenlei Li, Zheng Zhou, Jie Zhang, Wenjun Liang, Aibin |
author_facet | Yang, Meng Tian, Xiaoxue Fan, Zhuoyi Yu, Wenlei Li, Zheng Zhou, Jie Zhang, Wenjun Liang, Aibin |
author_sort | Yang, Meng |
collection | PubMed |
description | RAD51, is a key homologous recombination protein that repairs DNA damage and maintains gene diversity and stability. Previous studies have demonstrated that the over-expression of RAD51 is associated with chemotherapy resistance of tumor cells to chemotherapy, and enhanced activity of DNA damage repair (DDR) systems contributes to resistance of adult T-cell leukemia-lymphoma (ATL) resistance to chemotherapy. Thus, targeting RAD51 is a potential strategy for the sensitization of ATL cells to chemotherapeutic drugs by inducing DNA damage. In general, cells can repair minor DNA damage through DDR; however, serious DNA damage may cause cell toxicity in cells which cannot be restored. In the present, down regulation of RAD51 by shRNA and imatinib sensitized Jurkat cells to etoposide by decreasing the activity of homologous recombination (HR). We found that the suppression of RAD51 by shRNA inhibited tumor cells proliferation and enhanced apoptosis of Jurkat cells after etoposide treatment. Importantly, downregulation of RAD51 by imatinib obviously increased the apoptosis of Jurkat cell after etoposide treatment. These results demonstrated that RAD51 may be of great value to as a novel target for the clinical treatment of adult T-cell leukemia-lymphoma (ATL), and it may improve the survival of leukemia patients. |
format | Online Article Text |
id | pubmed-6859462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-68594622019-11-26 Targeting RAD51 enhances chemosensitivity of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand break repair Yang, Meng Tian, Xiaoxue Fan, Zhuoyi Yu, Wenlei Li, Zheng Zhou, Jie Zhang, Wenjun Liang, Aibin Oncol Rep Articles RAD51, is a key homologous recombination protein that repairs DNA damage and maintains gene diversity and stability. Previous studies have demonstrated that the over-expression of RAD51 is associated with chemotherapy resistance of tumor cells to chemotherapy, and enhanced activity of DNA damage repair (DDR) systems contributes to resistance of adult T-cell leukemia-lymphoma (ATL) resistance to chemotherapy. Thus, targeting RAD51 is a potential strategy for the sensitization of ATL cells to chemotherapeutic drugs by inducing DNA damage. In general, cells can repair minor DNA damage through DDR; however, serious DNA damage may cause cell toxicity in cells which cannot be restored. In the present, down regulation of RAD51 by shRNA and imatinib sensitized Jurkat cells to etoposide by decreasing the activity of homologous recombination (HR). We found that the suppression of RAD51 by shRNA inhibited tumor cells proliferation and enhanced apoptosis of Jurkat cells after etoposide treatment. Importantly, downregulation of RAD51 by imatinib obviously increased the apoptosis of Jurkat cell after etoposide treatment. These results demonstrated that RAD51 may be of great value to as a novel target for the clinical treatment of adult T-cell leukemia-lymphoma (ATL), and it may improve the survival of leukemia patients. D.A. Spandidos 2019-12 2019-10-22 /pmc/articles/PMC6859462/ /pubmed/31638261 http://dx.doi.org/10.3892/or.2019.7384 Text en Copyright: © Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Yang, Meng Tian, Xiaoxue Fan, Zhuoyi Yu, Wenlei Li, Zheng Zhou, Jie Zhang, Wenjun Liang, Aibin Targeting RAD51 enhances chemosensitivity of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand break repair |
title | Targeting RAD51 enhances chemosensitivity of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand break repair |
title_full | Targeting RAD51 enhances chemosensitivity of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand break repair |
title_fullStr | Targeting RAD51 enhances chemosensitivity of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand break repair |
title_full_unstemmed | Targeting RAD51 enhances chemosensitivity of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand break repair |
title_short | Targeting RAD51 enhances chemosensitivity of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand break repair |
title_sort | targeting rad51 enhances chemosensitivity of adult t-cell leukemia-lymphoma cells by reducing dna double-strand break repair |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859462/ https://www.ncbi.nlm.nih.gov/pubmed/31638261 http://dx.doi.org/10.3892/or.2019.7384 |
work_keys_str_mv | AT yangmeng targetingrad51enhanceschemosensitivityofadulttcellleukemialymphomacellsbyreducingdnadoublestrandbreakrepair AT tianxiaoxue targetingrad51enhanceschemosensitivityofadulttcellleukemialymphomacellsbyreducingdnadoublestrandbreakrepair AT fanzhuoyi targetingrad51enhanceschemosensitivityofadulttcellleukemialymphomacellsbyreducingdnadoublestrandbreakrepair AT yuwenlei targetingrad51enhanceschemosensitivityofadulttcellleukemialymphomacellsbyreducingdnadoublestrandbreakrepair AT lizheng targetingrad51enhanceschemosensitivityofadulttcellleukemialymphomacellsbyreducingdnadoublestrandbreakrepair AT zhoujie targetingrad51enhanceschemosensitivityofadulttcellleukemialymphomacellsbyreducingdnadoublestrandbreakrepair AT zhangwenjun targetingrad51enhanceschemosensitivityofadulttcellleukemialymphomacellsbyreducingdnadoublestrandbreakrepair AT liangaibin targetingrad51enhanceschemosensitivityofadulttcellleukemialymphomacellsbyreducingdnadoublestrandbreakrepair |